

**Policy and Procedure**

**PHARMACY PRIOR AUTHORIZATION  
AND STEP THERAPY  
POLICY AND CRITERIA  
ORPTCONC058B.0821**

**ANTINEOPLASTIC AGENTS  
RITUXIMAB**

See [Appendix A](#) for medications covered by policy

**Effective Date: 1/1/2022**



**Robert Gluckman, M.D.  
Chief Medical Officer**

Review/Revised Date: 08/06, 04/07, 12/08, 02/09, 12/09, 04/10, 06/11, 02/13, 06/13, 02/14, 02/15, 06/15, 07/15, 01/16, 12/16, 01/18, 04/18, 08/18, 01/19, 03/19, 09/19, 12/19, 01/20, 12/20, 04/21, 07/21 (JLS)

P&T Committee Meeting Date: 8/06, 4/07, 12/08, 2/09, 12/09, 04/10, 06/11, 02/13, 06/13, 02/14, 02/15, 06/15, 07/15, 02/16, 02/17, 02/18, 06/18, 10/18, 02/19, 04/19, 10/19, 12/19, 02/20, 06/20, 02/21, 04/21, 08/21

Original Effective Date: 08/06

Approved by: Oregon Region Pharmacy and Therapeutics Committee

Page

1 of 12

**SCOPE:**

Providence Health Plan, Providence Health Assurance, Providence Plan Partners, and Ayin Health Solutions as applicable (referred to individually as “Company” and collectively as “Companies”).

**APPLIES TO:**

Medicare Part B

**POLICY CRITERIA:**

**COVERED USES:**

All Food and Drug Administration (FDA) approved indications not otherwise excluded from the benefit, some medically- accepted indications.

**REQUIRED MEDICAL INFORMATION:**

- I. For initiation of therapy (new starts), both of the following criteria must be met:
  - a. For **non-preferred rituximab** products: Documented trial and failure, intolerance, or contraindication to the use of both of the preferred biosimilar medications: Ruxience® (rituximab-pvvr) and Truxima® (rituximab-abbs). See [Appendix A](#) for preferred and non-preferred rituximab products
  - b. Must meet criteria for specific indications, as outlined below:
    - i. For **Oncologic diagnoses:** For initial authorization: use must be for a FDA approved indication or indication supported by National Comprehensive Cancer Network (NCCN) guidelines with recommendation 2A or higher
    - ii. For **Rheumatoid Arthritis:**
      - 1. Documentation of trial, failure, intolerance, or contraindication to at least one of the following targeted immune modulators: etanercept (Enbrel®), adalimumab

**PHARMACY PRIOR AUTHORIZATION  
AND STEP THERAPY POLICY AND  
CRITERIA  
ORPTCONC058B**

**ANTINEOPLASTIC AGENTS  
RITUXIMAB**

- (Humira®), a preferred infliximab product or intravenous golimumab (Simponi® Aria), **AND**
2. Documentation that rituximab will be used concurrently with methotrexate. If intolerance or contraindication to methotrexate, then in combination with another disease-modifying antirheumatic drug (DMARD) (e.g., leflunomide, sulfasalazine, hydroxychloroquine), unless medical rationale is provided to support monotherapy.
  - iii. For **Vasculitis** – including antineutrophil cytoplasmic autoantibody (ANCA)-associated vasculitis [e.g., Granulomatosis with Polyangiitis (GPA) and Microscopic Polyangiitis (MPA)] and refractory polyarteritis nodosa (resistant to cyclophosphamide):
    1. Documentation that rituximab will be given in combination with glucocorticoids, **AND**
    2. Documentation of severe disease (e.g., critical organ system involvement)
  - iv. For **Immune Thrombocytopenia (ITP)**:
    1. Documentation of trial, failure, intolerance, or contraindication to systemic corticosteroid therapy, **AND**
    2. Documentation of active bleeding, or high-risk of bleeding, or a platelet count less than 30,000 cells per microliter
  - v. For **Relapsing and Remitting Multiple Sclerosis (RRMS)**: One of the following:
    1. Documentation of trial, failure, or intolerance to at least two disease modifying therapies indicated for RRMS, **OR**
    2. Documentation that patient has highly active or aggressive disease
  - vi. For **Refractory Myasthenia Gravis**:
    1. Documentation that patient has severely impaired function due to myasthenia gravis, **AND**
    2. Documented trial, failure, intolerance or contraindication to at least two of the following conventional therapies:
      - a. Acetylcholinesterase inhibitors (e.g., pyridostigmine)
      - b. Corticosteroids (e.g., prednisone, methylprednisolone)
      - c. Immunosuppressive agents (e.g., azathioprine, cyclosporine, mycophenolate)
      - d. Plasma exchange
  - vii. For **Autoimmune Hemolytic Anemia (AIHA)**:

**PHARMACY PRIOR AUTHORIZATION  
AND STEP THERAPY POLICY AND  
CRITERIA  
ORPTCONC058B**

**ANTINEOPLASTIC AGENTS  
RITUXIMAB**

1. In patients diagnosed with warm AIHA: Documentation of trial, failure, intolerance, or contraindication to glucocorticoids, **OR**
  2. In patients diagnosed with cold AIHA or cold agglutinin disease
- II. For **patients established on therapy** with the requested product (within the previous year): Documentation of adequate response to the medication must be provided.

**EXCLUSION CRITERIA:** N/A

**AGE RESTRICTIONS:** N/A

**PRESCRIBER RESTRICTIONS:**

Must be prescribed by, or in consultation with, an oncologist, rheumatologist, neurologist (in the case of RRMS, NMO), dermatologist (in the case of PV), or nephrologist (in the case of renal disease).

**COVERAGE DURATION:**

Initial authorization will be approved for six months and reauthorization will be approved for one year.

---

*For off-label use criteria please see the Chemotherapy Treatment Utilization Criteria; Coverage for Non-FDA Approved Indications ORPTCOPS105.*

*Requests for indications that were approved by the FDA within the previous six (6) months may not have been reviewed by the health plan for safety and effectiveness and inclusion on this policy document. These requests will be reviewed using the New Drug and or Indication Awaiting P&T Review; Prior Authorization Request ORPTCOPS047.*

*Requests for a non-FDA approved (off-label) indication requires the proposed indication be listed in either the American Hospital Formulary System (AHFS), Drugdex, or the National Comprehensive Cancer Network (NCCN) and is considered subject to evaluation of the prescriber's medical rationale, formulary alternatives, the available published evidence-based research and whether the proposed use is determined to be experimental/investigational.*

*Coverage decisions are made on the basis of individualized determinations of medical necessity and the experimental or investigational character of the treatment in the individual case.*

**INTRODUCTION:**

Rituximab binds to the CD20 antigen on B-lymphocytes and the Fc portion recruits immune functions to mediate B-cell lysis. Recombinant human hyaluronidase is an

**PHARMACY PRIOR AUTHORIZATION  
AND STEP THERAPY POLICY AND  
CRITERIA  
ORPTCONC058B**

**ANTINEOPLASTIC AGENTS  
RITUXIMAB**

endoglycosidase used to increase the dispersion and absorption of co-administered drugs when administered subcutaneously.

Rituximab has a boxed warning for severe mucocutaneous reactions, hepatitis B (HBV) reactivation, and progressive multifocal leukoencephalopathy (PML). Intravenous rituximab also has a boxed warning for fatal-infusion related reactions within 24 hours of administration. The majority of these reactions occur with the first infusion.

**FDA APPROVED INDICATIONS:**

Rituximab and biosimilars, injection for intravenous use

- Non-Hodgkin's Lymphoma (NHL)
  - Relapsed or refractory, low-grade or follicular, CD20-positive, B-cell NHL as a single agent
  - Previously untreated follicular, CD20-positive, B-cell NHL in combination with first line chemotherapy and, in patients achieving a complete or partial response to Rituxan in combination with chemotherapy, as single-agent maintenance therapy.
  - Non-progressing (including stable disease), low-grade, CD20-positive, B-cell NHL as a single agent after first-line CVP chemotherapy
  - Previously untreated diffuse large B-cell, CD20-positive NHL in combination with CHOP or other anthracycline-based chemotherapy regimens
- Chronic Lymphocytic Leukemia (CLL): in combination with fludarabine and cyclophosphamide (FC) for the treatment of patients with previously untreated and previously treated CD20-positive CLL
- Granulomatosis with Polyangiitis (GPA) (Wegener's Granulomatosis) and Microscopic Polyangiitis (MPA) in adult and pediatric patients 2 years of age and older in combination with glucocorticoids

Rituxan® and Truxima® only

- Rheumatoid Arthritis (RA): (Moderate to Severe), in combination with methotrexate, in patients who had an inadequate response to one or more tumor-necrosis-factor (TNF) antagonist therapies

Rituxan® only

- Moderate to severe Pemphigus Vulgaris (PV) in adult patients

Limitations of use: Rituxan® is not recommended for use in patients with severe, active infection.

Rituxan Hycela® (rituximab and hyaluronidase) injection

- Follicular Lymphoma

**PHARMACY PRIOR AUTHORIZATION  
AND STEP THERAPY POLICY AND  
CRITERIA  
ORPTCONC058B**

**ANTINEOPLASTIC AGENTS  
RITUXIMAB**

- Relapsed or refractory, follicular lymphoma as a single agent
- Previously untreated follicular lymphoma in combination with first line chemotherapy and, in patients achieving a complete or partial response to rituximab in combination with chemotherapy, as single-agent maintenance therapy
- Non-progressing (including stable disease), follicular lymphoma as a single agent after first-line cyclophosphamide, vincristine, and prednisone (CVP) chemotherapy
- Diffuse Large B-cell Lymphoma
  - Previously untreated diffuse large B-cell lymphoma in combination with cyclophosphamide, doxorubicin, vincristine, prednisone (CHOP) or other anthracycline-based chemotherapy regimens
- Chronic Lymphocytic Leukemia
  - Previously untreated and previously treated CLL in combination with fludarabine and cyclophosphamide (FC)

**Limitations of Use:**

- Initiate treatment only after patients have received at least one full dose of a rituximab product by intravenous infusion.
- Not indicated for the treatment of non-malignant conditions.

**POSITION STATEMENT:**

Information to date suggests that patients with **rheumatoid arthritis** (RA) who receive rituximab have an increased risk of progressive multifocal leukoencephalopathy (PML). Physicians should consider the risk of PML in any patient treated with rituximab who presents with new onset neurologic manifestations. Consultation with a neurologist, brain magnetic resonance imaging (MRI) scan, and lumbar puncture should be considered as clinically indicated. The American College of Rheumatology guidelines, updated in 2015, recommend rituximab for use in certain populations including patients who were previously treated for lymphoproliferative disorders such as B-cell chronic lymphocytic leukemia, non-Hodgkin lymphoma, hairy cell leukemia.

**Vasculitis** is a term for a general condition that causes inflammation of blood vessels that can lead to occlusion or rupture of the vessels. This can have devastating effects to organ systems, including ischemia or hemorrhage. The cause is unknown in most cases, but certain infections [human immunodeficiency virus (HIV), Hepatitis B] and autoimmune conditions (e.g., rheumatoid arthritis) can be considered risk factors. Diagnosis is typically done through biopsy, angiography and other blood tests.

**PHARMACY PRIOR AUTHORIZATION  
AND STEP THERAPY POLICY AND  
CRITERIA  
ORPTCONC058B**

**ANTINEOPLASTIC AGENTS  
RITUXIMAB**

Granulomatosis with polyangiitis (GPA), also known as Wegener's granulomatosis, is an uncommon subset of vasculitis that is characterized by inflammation of blood vessels that primarily affect the upper airways, lungs, and kidneys. Typically, symptoms start in the sinuses and can progress rapidly to organ systems like the kidneys, ultimately causing organ failure or dysfunction (e.g., glomerulonephritis). Microscopic polyangiitis (MPA) is another uncommon form of vasculitis that primarily affects small to medium sized blood vessels in the kidneys, lung, nerves, skin, and joints. Symptoms are related to the affected organ system (e.g., muscle/joint pain, or dermatologic rash). Both GPA and MPA are commonly associated with antineutrophil cytoplasmic autoantibody (ANCA), approximately 80 to 90% of patients are found to have ANCA. Although GPA and MPA are distinct entities within ANCA-associated vasculitis, they have been classified together due to their overlapping manifestations and it can be extremely difficult to differentiate between the two diseases. Experts commonly recognize ANCA antigen types for myeloperoxidase (anti-MPO) or proteinase 3 (anti-PR3), rather than by disease type (GPA or MPA).<sup>5, 6, 13, 14, 25</sup>

The 2015 European League Against Rheumatism (EULAR) update for management of ANCA-associated vasculitis (AAV) was developed in collaboration with the European Renal Association-European Dialysis and Transplant Association (ERA-EDTA) and the European Vasculitis Association (EUVAS)<sup>26</sup>:

- For remission-induction and major relapse of new-onset organ-threatening or life-threatening AAV, it is recommended to treat with high-dose glucocorticoid therapy in combination with **rituximab** or cyclophosphamide for GPA and MPA (Grade A recommendation)
  - Two randomized controlled trials investigated the use of rituximab in AAV, the RAVE and RITUXVAS trials in patients with GPA and MPA.
  - In both studies, patients received high-dose glucocorticoids with rituximab 375 mg/m<sup>2</sup> weekly
  - Rituximab was non-inferior to cyclophosphamide in both trials
  - Rituximab appeared more effective for relapsing disease in RAVE trial, therefore it is preferred over cyclophosphamide for relapsing disease per EULAR/ERA-DTA recommendations
- Glucocorticoid plus rituximab or cyclophosphamide combination therapy is also recommended with a lower grade of evidence for eosinophilic granulomatosis with polyangiitis (EGPA) which is also known as Churg-Strauss syndrome.
- For remission-induction in non-organ-threatening disease in AAV, EULAR recommends combination of glucocorticoid and either methotrexate or mycophenolate mofetil. .

**PHARMACY PRIOR AUTHORIZATION  
AND STEP THERAPY POLICY AND  
CRITERIA  
ORPTCONC058B**

**ANTINEOPLASTIC AGENTS  
RITUXIMAB**

- Maintenance of remission is achieved by use of low-dose glucocorticoids plus either azathioprine, rituximab, methotrexate, or mycophenolate mofetil (listed in order of the strength of voting by the expert panel who developed the EULAR/ERA-DTA recommendations).
  - Leflunomide is no longer considered first-line therapy for remission maintenance due to more adverse effects compared to the immunosuppressants listed above
- For patients with recurrent infections, rituximab is associated with hypogammaglobulinemia, therefore it is recommended to test serum immunoglobulin levels prior to course of rituximab

The use of rituximab for polyarteritis nodosa (PAN) is supported by its efficacy in ANCA-associated vasculitis. PAN is a systemic vasculitis that is treated with glucocorticoids and cyclophosphamide in severe cases. Case reports have shown successful treatment by rituximab for life-threatening polyarteritis nodosa that did not respond to glucocorticoids and cyclophosphamide.

**Immune thrombocytopenia (ITP)** is also known as immune thrombocytopenic purpura or idiopathic thrombocytopenic purpura. This is an autoimmune disease characterized by immunologic destruction of otherwise normal platelets and is typically caused by an unknown trigger. First line treatment is typically with corticosteroids when the platelet count is  $< 30 \times 10^9/L$ . Immune globulin (IgG) can be considered for add-on therapy (one-time dose) when a rapid increase in platelet count is needed. Second-line treatments include splenectomy, TPO-receptor agonists (e.g., eltrombopag, romiplostim), and rituximab. Splenectomy is the only treatment that provides sustained remission off all treatments at one year and beyond in a high proportion of ITP patients.

Current clinical evidence of the treatment of **relapsing remitting multiple sclerosis (RRMS)** with rituximab is limited. A 2013 systemic Cochrane review of rituximab for RRMS demonstrated that there was only one randomized, placebo, controlled trial published, and that the overall quality was poor<sup>8</sup>. The trial involved 104 adult patients with RRMS, randomized to receive either rituximab or placebo on days 1 and 15 of study, and patients were followed for 48 weeks. Primary outcomes were reduction of gadolinium-enhancing lesions and the annualized rate of relapse. The study showed that those receiving rituximab had a reduction in lesions at week 24 as compared to those in the placebo group (mean number 0.5 versus 5.5; RR 91%,  $P < 0.001$ ); those in the treatment group had a statistically significant reduction in the annualized rate of relapse compared to placebo at week 24 (0.37 versus 0.84,  $P = 0.04$ ), but not at week 48 (0.37 versus 0.84,  $P = 0.08$ ). However, the Cochrane review points out the high attrition bias in the study as overall 24% of enrolled patients dropped out before 48 weeks; 40% of those in the placebo group dropped

**PHARMACY PRIOR AUTHORIZATION  
AND STEP THERAPY POLICY AND  
CRITERIA  
ORPTCONC058B**

**ANTINEOPLASTIC AGENTS  
RITUXIMAB**

out before the 48 week mark. Therefore, there is limited evidence to support the use of rituximab for the treatment of RRMS, and additional long-term randomized trials are needed. A comprehensive review on the treatment of multiple sclerosis by Gholamzad et al. 2019 suggested that rituximab for RRMS patients who did not respond to first- and second-line therapies and in cases where RRMS is stabilized after natalizumab treatment and is a candidate for a RRMS therapy with less PML risk.

Current clinical evidence of the treatment of **pemphigus vulgaris (PV)** is limited. PV is an acquired autoimmune disease in which immunoglobulin (IgG) antibodies target desmosomal proteins to produce intraepithelial, mucocutaneous blistering. A non-U.S.-approved rituximab product in combination with short-term prednisone was compared to prednisone monotherapy (1:1) as first-line treatment in 90 newly diagnosed adult patients with moderate to severe pemphigus (74 PV). This was a randomized, open-label, controlled study. 66 of the patients with PV had severe disease according to disease severity defined by Harman's criteria. Study treatment included an initial IV infusion of 1 gram of non-U.S. approved rituximab product in combination with a short-term regimen of 0.5mg/kg/day of oral prednisone tapered over 3 months for moderate disease and 1mg/kg/day for severe disease tapered over 6 months. All patients received a second IV infusion of 1g on day 15. Maintenance infusions of 500mg were administered at months 12 and 18. In the prednisone arm, patients received 1mg/kg/day of oral prednisone tapered off over 12 months for moderate disease and 1.5mg/kg/day oral prednisone tapered over 18 months for severe disease. The primary endpoint was complete remission at month 24 without the use of prednisone therapy for 2 months or more. Non-U.S.-approved rituximab product plus prednisone had an 89% response rate and 90% response rate among the 38 PV patients compared to only a 34% response rate among prednisone monotherapy (28% of 36 PV patients).

**Glomerulonephritis** is inflammation of the tiny filters (glomeruli) in the kidneys. Glomeruli remove excess fluid, electrolytes and waste from the bloodstream and pass them into the urine. Glomerulonephritis occurs on its own or as part of another disease (e.g. lupus or diabetes) and can be either acute or chronic. Severe or prolonged inflammations associated with glomerulonephritis can result in kidney failure, chronic kidney disease, high blood pressure and nephrotic syndrome. Many conditions can cause glomerulonephritis which include infections, immune disease (e.g. systemic lupus erythematosus), and vasculitis (e.g. granulomatosis with polyangiitis). Treatment of glomerulonephritis depends on the underlying cause(s) and severity of the condition. Rituximab is a recommended option in systemic lupus erythematosus (SLE) nephritis in both European League against Rheumatism (EULAR) and American College of Rheumatology guidelines.



**Autoimmune hemolytic anemia (AIHA)** is a group of disorders characterized by a malfunction of the immune system that produces autoantibodies, which attack red blood cells as if they were substances foreign to the body. There are no randomized, controlled prospective trials to compare relative effectiveness of the different treatment options.

- There are two main types of AIHA: Warm AIHA where the autoantibodies attach to and destroy red blood cells (RBC) at normal body temperature and cold AIHA (cold agglutinin disease) where the autoantibodies (IgM) become most active and attack RBC only at temperatures well below normal body temperature.
- Treatment strategy in warm AIHA includes reduction in autoantibody production (e.g. glucocorticoids, rituximab) and reduction in autoantibody effectiveness (e.g. splenectomy)
  - First-line agent is glucocorticoids at an initial dose of 1 to 1.5 mg/kg per day of prednisone or its equivalent in adults.
  - Second-line agents include splenectomy or rituximab, although splenectomy is more likely to achieve long-term cure.
  - Third-line agents include immunosuppressive or cytotoxic agents
- Treatment strategy in cold AIHA (cold agglutinin disease [CAD]) include minimizing cold-induced symptoms, maintaining an acceptable hemoglobin level, and addressing underlying disorders. Glucocorticoids and splenectomy are not effective therapy in CAD. Rituximab-containing regimens are usually recommended as first-line.

**Neuromyelitis optica (NMO)**, previously known as Devic disease, is an autoimmune inflammatory disorder that typically affects the optic nerves and spinal cord.<sup>16</sup> Prophylactic treatment of NMO recurrence must be immediately performed when NMO is identified because the progression of NMO disability is related to the severity of attacks.

The pathogenesis of NMO is related to the presence of aquaporin-4 autoantibody, thus, rituximab has been often utilized as treatment given its activity against CD20. The depletion of CD20 provides a theoretical basis for treatment of autoimmune diseases, in which B cells and autoantibodies play a key role; for example, AQP4-Ab is associated with NMO. A meta-analysis of 26 studies with 577 participants was conducted to evaluate rituximab efficacy in terms of safety and tolerance and assessed the treatment efficacies based on relapse rates and disability. Antibodies against aquaporin-4 autoantibody were recorded in 435 of 577 (75.39%) patients with NMO. Rituximab therapy resulted in a mean  $-1.56$  (95% CI,  $-1.82$  to  $-1.29$ )

**PHARMACY PRIOR AUTHORIZATION  
AND STEP THERAPY POLICY AND  
CRITERIA  
ORPTCONC058B**

**ANTINEOPLASTIC AGENTS  
RITUXIMAB**

reduction in the mean ARR ratio and a mean – 1.16 (95% CI, – 1.36 to – 0.96) reduction in the mean EDSS score. A total of 330 of 528 patients (62.9%) reached the relapse-free state. A total of 95 of 577 (16.46%) patients had adverse reactions.<sup>17</sup>

**REFERENCE/RESOURCES:**

1. Rituxan In: DRUGDEX® System [Internet database]. Greenwood Village, CO: Thomson Reuters (Healthcare) Inc.; Updated periodically. Accessed January 10, 2020.
2. Rituxan® package insert. South San Francisco, CA: Genentech; 2020 Aug.
3. NCCN Practice Guidelines in Oncology v.2.2019
4. Singh JA, Saag KG, Bridges SL Jr, et al. 2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis. *Arthritis Care Res.* 2015; doi 10.1002/acr.22783
5. Mukhtyar C, Guillevin L, Cid MC et al. EULAR recommendations for the management of primary small and medium vessel vasculitis. *Ann Rheum Dis.* 2009;68(3):310-7.
6. Villa-Forte A, European League Against Rheumatism, European Vasculitis Study Group. European League Against Rheumatism/European Vasculitis Study Group recommendations for the management of vasculitis. *Curr Opin Rheumatol.* 2010;22(1):49-53.
7. Neunert C, Terrell DR, Arnold DM et al. American Society of Hematology 2019 guidelines for immune thrombocytopenia. *Blood Adv.* 2019;3(23):3829-3866. Erratum in: *Blood Adv.* 2020;4(2):252.
8. He D, Guo R, Zhang F et al. Rituximab for relapsing-remitting multiple sclerosis. *Cochrane Database Syst Rev.* 2013;(12):CD009130. doi (12):CD009130.
9. Sanders DB, Wolfe GI, Benatar M, et al. International consensus guidance for management of myasthenia gravis-Executive Summary. *Neurology.* 2016 Jul 26; 87(4): 419-25.
10. Harman KE, Brown D, Exton LS, et al. British association of dermatologists' guidelines for the management of pemphigus vulgaris 2017. *Br J Dermatol.* 2017 Nov; 177(5):1170-1202.
11. Merck Manual. Autoimmune Hemolytic Anemia. <https://www.merckmanuals.com/home/blood-disorders/anemia/autoimmune-hemolytic-anemia> (accessed on 1/15/2019)
12. Brugnara C, Brodsky R. Warm autoimmune hemolytic anemia in Adults (last updated 08/07/2020). In: UpToDate, Post, TW (Ed), UpToDate, Waltham, MA, 2019.

**PHARMACY PRIOR AUTHORIZATION  
AND STEP THERAPY POLICY AND  
CRITERIA  
ORPTCONC058B**

**ANTINEOPLASTIC AGENTS  
RITUXIMAB**

13. Mayo Clinic. Glomerulonephritis. <https://www.mayoclinic.org/diseases-conditions/glomerulonephritis/symptoms-causes/syc-20355705> (accessed on 1/15/2019)
14. Mayo Clinic. Vasculitis. Available at <https://www.mayoclinic.org/diseases-conditions/vasculitis/symptoms-causes/syc-20363435> (Accessed March 19, 2019).
15. Langford CA. Update on the treatment of granulomatosis with polyangiitis (Wegener's). *Curr Treat Options Cardiovasc Med.* 2012;14(2):164-76.
16. Pittock SJ, Berthele A, Fujihara K et al. Eculizumab in Aquaporin-4–Positive Neuromyelitis Optica Spectrum Disorder. *N. Engl. J. Med.* 2019; 381:614-625.
17. Gao F, Chai B, Gu C et al. Effectiveness of rituximab in neuromyelitis optica: a meta-analysis. *BMC Neurology.* 2019; 19:36.
18. Trebst C, Jarius S, Berthele A, et al. Update on the diagnosis and treatment of neuromyelitis optica: recommendations of the Neuromyelitis Optica Study Group (NEMOS). *J Neurol.* 2014;261(1):1–16.
19. Kimbrough DJ, Fujihara K, Jacob A, et al. Treatment of Neuromyelitis Optica: Review and Recommendations. *Mult Scler Relat Disord.* 2012;1(4):180–187.
20. Sellner J, Boggild M, Clanet M et al. EFNS guidelines on diagnosis and management of neuromyelitis optica. *European Journal of Neurology.* 2010; 17:1019-1032.
21. Stellmann JP, Krumbholz M, Friede T et al. Immunotherapies in neuromyelitis optica spectrum disorder: efficacy and predictors of response. *J Neurol Neurosurg Psychiatry.* 2017; 88(8): 639-647.
22. Scott TF, Frohman EM, De Seze J. Evidence-based guideline: Clinical evaluation and treatment of transverse myelitis: Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. *Neurology* 2011; 77: 2128-34.
23. Mealy MA, Wingerchuk DM, Palace J, et al. Comparison of Relapse and Treatment Failure Rates Among Patients With Neuromyelitis Optica: Multicenter Study of Treatment Efficacy. *JAMA Neurol.* 2014 Jan 20.
24. Wingerchuk DM, Banwell B, Bennet JL et al. International consensus diagnostic criteria for neuromyelitis optica spectrum disorders. *Neurology.* 2015;85(2).
25. Schioppo T, Ingegnoli F. Current perspective on rituximab in rheumatic diseases. *Drug Design, Development and Therapy.* 2017; 11: 2891-2904
26. Yates M, Watts RA, Bajema IM, et al. EULAR/ERA-EDTA recommendations for management of ANCA-associated vasculitis. *Ann Rheum Dis.* 2016; 75(9): 1583-94
27. Seri Y, Shoda H, Hanata N, et al. A case of refractory polyarteritis nodosa successfully treated with rituximab. *Mod Rheumatol.* 2017; 27(4): 696-698

**PHARMACY PRIOR AUTHORIZATION  
AND STEP THERAPY POLICY AND  
CRITERIA  
ORPTCONC058B**

**ANTINEOPLASTIC AGENTS  
RITUXIMAB**

28. Ribeiro E, Cressend T, Duffau P, et al. Rituximab Efficacy during a Refractory Polyarteritis Nodosa Flare. *Case Rep Med.* 2009; doi: 10.1155/2009/738293. Epub 2010 Mar 14.
29. Lucchini E, Zaja F, Bussel J. Rituximab in treatment of immune thrombocytopenia: what is the role of this agent in 2019. *Haematologica.* 2019; 104(6): 1124-1135
30. Ghloamzad M, Ebtekar M, Ardestani MS, et al. A comprehensive review on the treatment approaches of multiple sclerosis: currently and in the future. *Inflammation Research.* 2019; 68:25-38
31. Jäger U, Barcellini W, Broome CM, et al. Diagnosis and treatment of autoimmune hemolytic anemia in adults: Recommendations from the First International Consensus Meeting. *Blood Rev.* 2020 May;41:100648.
32. Michalak SS, Olewicz-Gawlik A, Rupa-Matysek J, Wolny-Rokicka E, Nowakowska E, Gil L. Autoimmune hemolytic anemia: current knowledge and perspectives. *Immun Ageing.* 2020 Nov 20;17(1):38.
33. Rituxan Hycela® package insert. South San Francisco, CA: Genentech; 2020 May
34. Truxima® package insert. North Wales, PA: Teva Pharmaceuticals; 2020 May.
35. Ruxience® package insert. New York, NY: Pfizer; 2020 May.
36. Riabni® package insert. Thousand Oaks, CA: Amgen, Inc; 2020 Dec.

**APPENDIX A.**

<b>Brand Name</b>	<b>Generic Name</b>	<b>HCPCS Code</b>
<i>Preferred Products</i>		
<b>Ruxience®</b>	rituximab-pvvr	Q5119
<b>Truxima®</b>	rituximab-abbs	Q5115
<i>Non-preferred Products</i>		
<b>Riabni®</b>	rituximab-arrx	J3590
<b>Rituxan®</b>	rituximab infusion	J9312
<b>Rituxan Hycela®</b>	rituximab & hyaluronidase infusion	J9311